Carralot J-P, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee H-G, Pascolo S
CureVac GmbH, Paul Ehrlich Strasse 15, 72076 Tübingen, Germany.
Cell Mol Life Sci. 2004 Sep;61(18):2418-24. doi: 10.1007/s00018-004-4255-0.
In the context of developing a safe genetic vaccination strategy we tested and studied globin-stabilized mRNA-based vaccination in mice. This vaccination strategy has the advantages of genetic vaccination (easy production, adaptability to any disease and inexpensive storage when lyophilized), but not the drawbacks of DNA vaccination (long-term uncontrolled expression of a transgene, possibility of integration into the host genome and possible induction of anti-DNA antibodies). We report here that injection of naked beta-globin untranslated region (UTR)-stabilized mRNA coding for beta-galactosidase is followed by detectable translation in vivo. In addition, we show that such a vaccination strategy primes a T helper 2 (Th2) type of response which can be enhanced and shifted to a Th1-type immune response by application of recombinant granulocyte/macrophage colony-stimulating factor 1 day after mRNA injection. Our data demonstrate that the administration of globin UTR-stabilized mRNA is a versatile vaccination strategy that can be manipulated to fit the requirement of antiviral, antibacterial or antitumor immunity.
在制定安全的基因疫苗接种策略的背景下,我们在小鼠中测试并研究了基于珠蛋白稳定化mRNA的疫苗接种。这种疫苗接种策略具有基因疫苗接种的优点(易于生产、对任何疾病的适应性以及冻干时储存成本低廉),但没有DNA疫苗接种的缺点(转基因的长期不受控制的表达、整合到宿主基因组的可能性以及可能诱导抗DNA抗体)。我们在此报告,注射编码β-半乳糖苷酶的裸β-珠蛋白非翻译区(UTR)稳定化mRNA后,在体内可检测到翻译。此外,我们表明,这种疫苗接种策略引发了2型辅助性T细胞(Th2)反应,在mRNA注射后1天应用重组粒细胞/巨噬细胞集落刺激因子可增强该反应并将其转变为Th1型免疫反应。我们的数据表明,珠蛋白UTR稳定化mRNA的给药是一种通用的疫苗接种策略,可以进行调整以满足抗病毒、抗菌或抗肿瘤免疫的需求。